Lipid-lowering therapy in Switzerland: time trends in utilization and cost, 2015–2023

We showed increasing LLT utilization, primarily driven by new combinations of established drugs. PCSK9 inhibitors are still rarely utilized, however, they have substantially influenced the observed increase in cost.